Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Development Programs to Focus on GI and Inflammation Therapies with Reduced, or No, Side Effects
Establishment of a debt financing plan for a maximum amount of 15 million euros, with IPF Partners
Edgewater Capital Partners announced that they have entered into an agreement to acquire Haematologic Technologies Incorporated, a leading provider of biologic products and GMP compliant assay development and testing services to the biopharmaceutical industry.
Reported Additional Positive Phase 2 Data Showing Ridinilazole Improved Quality of Life and Microbiome Preservation Compared to Standard of Care
Sydney, Australia, 10 October 2019: Recce Pharmaceuticals Ltd, developing a new class of synthetic antibiotics, is pleased to announce it has raised AU$6,768,444.28 in a placement to institutional, professional and sophisticated investors that will result in 26,032,478 fully paid ordinary shares being issued at AU$0.26 per share
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced that it will attend several upcoming international conferences.
Heidelberg Pharma AG reported on the first nine months of fiscal year 2019 and the Group’s financial figures.
Datavant, the leader in helping healthcare organizations connect and share health data, announced a series of corporate updates.
UCB indicates the deal is part of its strategic growth plan, dubbed the “Accelerate and Expand” phase since 2019.
Global Blood Therapeutics, Inc., announced that on October 1, 2019, the compensation committee of GBT’s board of directors granted 12 new employees options to purchase an aggregate of 24,600 shares of the company’s common stock with a per share exercise price of $46.99 and restricted stock units for an aggregate of 57,050 shares of the company’s common stock.